Reference entry · GHRH(1-29) analog
Sermorelin
Also known as: GHRH(1-29) · GRF 1-29 · Geref
- Class
- GHRH(1-29) analog
- Size
- 29 amino acids
- Primary targets (literature)
- GHRH receptor → pituitary GH / IGF-1 axis
- Regulatory context
- Formerly FDA-approved (Geref); not currently marketed as branded U.S. drug. Compounded and RUO sermorelin require independent batch identity confirmation.
Overview
Sermorelin is the classical GHRH(1-29) analog with FDA approval history for pediatric GH deficiency (Geref, withdrawn commercially). Short half-life distinguishes it from tesamorelin and DAC-modified CJC-1295.
Mechanism in research literature
GHRH receptor agonism at the pituitary stimulates GH release and downstream IGF-1. [Nle27] substitution stabilizes the peptide relative to unmodified GHRH(1-29).
Common research focus areas
- Pediatric GH deficiency diagnosis and growth promotion
- Adult somatotropic axis restoration studies
- Pharmacokinetic comparison vs. longer GHRH analogs
- Sequence verification vs. mod GRF and tesamorelin mislabeling
Full literature roundup
Read the cited research summary
The GHRH(1-29) analog with decades of formal GH-stimulation research. Pediatric approval history, adult somatotropic literature, and catalog identity concerns.
Sermorelin research roundup · 6 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.